Objectives: The current study aims to evaluate safety and efficacy of topical calcipotriol/betamethasone dipropionate ointment versus topical betamethasone dipropionate cream alone in the treatment of localized plaque psoriasis using EID score (Erythema, Induration, Desquamation) as efficacy parameter. Methods: A total of 30 patients were enrolled in this 4-weeks study. Two plaques of chronic stable plaque psoriasis in the same patient with identical EID score were selected randomly. Patient applied topical calcipotriol hydrate plus betamethasone dipropropionate ointment (group A) on one plaque and topical betamethasone dipropionate 0.05% cream on the other plaque (group B) twice daily without occlusion. Patients were evaluated at the end of 2 and 4 weeks and EID scores were compared. Reduction of 75% of EID score (EID 75) was considered as successful treatment outcome. Results: Out of 30 patients, 26 patients completed the study. Mean baseline EID scores in both groups were identical (6.16__ampersandsignplusmn;1.19SD versus 6.16__ampersandsignplusmn;1.19SD). At the end of 2 weeks, EID 75 was achieved in 15.38% (4/26) lesions in group A as compared to 7.69% (2/26) in group B (P value-0.66, Fisher__ampersandsignrsquo;s exact test). At the end of 4 weeks, group A showed a significant clinical improvement in 69.23% of cases (18/26) while in group B, EID 75 was achieved in 26.92% (7/26) lesions (P value-0.005, Fisher__ampersandsignrsquo;s exact test). Both topical treatments were well tolerated. Conclusion: Our pilot study demonstrates higher efficacy of calcipotriol/betamethasone dipropionate ointment than betamethasone dipropionate cream alone in the treatment of localized plaque psoriasis at the end of 4 weeks.